Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation.

The AML1 transcription factor is essential for normal hematopoiesis and is the target of several chromosomal translocations in acute leukemia. Acquired somatic AML1 mutations were recently demonstrated sporadically in de novo myelodysplasia (MDS) and acute myeloid leukemia (AML) including a few cases of therapy-related disease (t-MDS/t-AML). We examined 140 patients with t-MDS or t-AML for AML1 mutations by direct sequencing. We identified 9 missense, 3 nonsense, and 10 frameshift mutations, all heterozygous, in 22 patients (15.7%). Thirteen mutations were located in the N-terminal Runt homology domain (RHD), whereas 9 mutations were located in the C-terminal region including the transactivation domain (TAD). Nineteen patients with AML1 mutations had previously received alkylating agents whereas 2 patients had received radiotherapy only. AML1 mutations were highly significantly associated with presentation of the disease as t-MDS (P =.003), with deletion or loss of chromosome arm 7q (P =.001) and with subsequent transformation to overt t-AML (P =.0001). Patients with missense mutations presented a shorter survival compared with patients with nonsense/frameshift mutations (P =.03). Our results suggest that AML1 mutations and deletion of genes on chromosome arm 7q cooperate in leukemogenesis and predispose to leukemic transformation.

[1]  R. Berger,et al.  P53 gene mutations in acute myeloid leukemia with 17p monosomy. , 1991, Blood.

[2]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[3]  E. Macintyre,et al.  High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. , 2000, Blood.

[4]  Yoshiaki Ito,et al.  In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. , 2002, Blood.

[5]  C. Preudhomme,et al.  New mechanisms of AML1 gene alteration in hematological malignancies , 2003, Leukemia.

[6]  M. Kurokawa,et al.  Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. , 2000, Blood.

[7]  M. Cleary,et al.  Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins , 2001, Oncogene.

[8]  J. Rowley,et al.  Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. , 1981, Blood.

[9]  Zhijian Qian,et al.  Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Kaneko,et al.  TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. , 1995, Blood.

[11]  D. Christiansen,et al.  Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Andersen,et al.  Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. , 2002, Blood.

[13]  L. Shih,et al.  Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia , 2004, Leukemia.

[14]  M. Taniwaki,et al.  Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia , 1997, Leukemia.

[15]  M. Taniwaki,et al.  Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype , 1999, Leukemia.

[16]  D. Christiansen,et al.  Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy , 2001, Leukemia.

[17]  R. Liang,et al.  Aberrant p15 gene promoter methylation in therapy‐related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations , 2003, British journal of haematology.

[18]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[19]  T. Kyo,et al.  High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. , 2004, Blood.

[20]  J. Licht,et al.  Translocations of the RARalpha gene in acute promyelocytic leukemia. , 2001, Oncogene.

[21]  R. Larson,et al.  Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Larsen,et al.  Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. , 1990, Blood.

[23]  H. Yamasaki,et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. , 1999, Blood.

[24]  大里 元美.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2 α B gene associated with myeloblastic leukemias , 1999 .

[25]  A. Hagenbeek,et al.  A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. , 2001, Blood.

[26]  Hamish S Scott,et al.  AML1 Interconnected Pathways of Leukemogenesis , 2003, Cancer investigation.

[27]  L. Maquat.  Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics , 2004, Nature Reviews Molecular Cell Biology.

[28]  J. Licht,et al.  Translocations of the RARα gene in acute promyelocytic leukemia , 2001, Oncogene.

[29]  J. Downing.  The core-binding factor leukemias: lessons learned from murine models. , 2003, Current opinion in genetics & development.

[30]  J. Pedersen‐Bjergaard,et al.  Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. , 1995, Blood.

[31]  H. Kanegane,et al.  Functional analysis of RUNX2 mutations in cleidocranial dysplasia: novel insights into genotype-phenotype correlations. , 2003, Blood cells, molecules & diseases.

[32]  D. Christiansen,et al.  Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia , 2003, Leukemia.

[33]  D. Gilliland,et al.  Core-binding factors in haematopoiesis and leukaemia , 2002, Nature Reviews Cancer.

[34]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[35]  M. Andersen,et al.  Cytogenetically unrelated clones in therapy‐related myelodysplasia and acute myeloid leukemia: Experience from the Copenhagen series updated to 180 consecutive cases , 1998, Genes, chromosomes & cancer.

[36]  Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. , 1997 .

[37]  L. Nagarajan,et al.  Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. , 2000, Blood.

[38]  M. Caligiuri,et al.  The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Inaba,et al.  Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. , 2003, Blood.

[40]  B. Quesnel,et al.  Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. , 1998, Blood.